MSH2 Loss in Primary Prostate Cancer

PURPOSE: Inactivation of mismatch repair (MMR) genes may predict sensitivity to immunotherapy in metastatic prostate cancers. We studied primary prostate tumors with MMR defects. EXPERIMENTAL DESIGN: 1133 primary prostatic adenocarcinomas and 43 prostatic small cell carcinomas (NEPC) were screened b...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Guedes, Liana B., Antonarakis, Emmanuel S., Schweizer, Michael T., Mirkheshti, Nooshin, Almutairi, Fawaz, Park, Jong Chul, Glavaris, Stephanie, Hicks, Jessica, Eisenberger, Mario A., De Marzo, Angelo M., Epstein, Jonathan I., Isaacs, William B., Eshleman, James R., Pritchard, Colin C., Lotan, Tamara L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5690834/
https://ncbi.nlm.nih.gov/pubmed/28790115
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0955
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados